UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer ...

Biogen (BIIB) reported third-quarter 2024 adjusted earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate of $3.77. While earnings declined 6% year over year on a reported basis, it remained flat on a constant-currency basis. Total revenues came in at $2.47 billion, down 3% year over year on both reported and constant-currency basis. This decline was due to lower sales of key multiple sclerosis (MS) drugs like Tecfidera and Tysabri as well as spinal muscular atrophy (SMA) drug Spinraza, ...

Biogen Inc. (NASDAQ:BIIB) Q3 2024 Earnings Call Transcript October 30, 2024 8:30 AM ET Company Participants Stephen Amato - Senior Director of IR Chris Viehbacher - President and CEO Priya Singhal - Head of Development Mike McDonnell - CFO Alisha Alaimo - Head & President of North America Conference Call Participants Brian Abrahams - RBC Capital Markets Phil Nadeau - TD Cowen Marc Goodman - Leerink Salveen Richter - Goldman Sachs Michael Yee - Jefferies Umer Raffat - Evercore ISI Jay Olson - Oppenheimer Eva ...

For the quarter ended September 2024, Biogen Inc. (BIIB) reported revenue of $2.47 billion, down 2.6% over the same period last year. EPS came in at $4.08, compared to $4.36 in the year-ago quarter. The reported revenue represents a surprise of +0.92% over the Zacks Consensus Estimate of $2.44 billion. With the consensus EPS estimate being $3.77, the EPS surprise was +8.22%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stree ...

| --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|----------------------------------------------------------|-------|------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Third Quarter 2024 Financial Results and Business Update | | October 30, 2024 | | | | | | | | | | | | | | | | | | Forward-looking statements This presentation and the discussions during this conference call contain forward-looking statements, r ...

Biogen Inc. (BIIB) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $3.77 per share. This compares to earnings of $4.36 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 8.22%. A quarter ago, it was expected that this company would post earnings of $4 per share when it actually produced earnings of $5.28, delivering a surprise of 32%. Over the last four quarters, the company has surpas ...

Press Release Cambridge, Mass. – October 30, 2024 Biogen reports third quarter 2024 results and raises full year 2024 financial guidance Third quarter 2024 revenue $2.5 billion; GAAP diluted EPS $2.66; Non-GAAP diluted EPS $4.08 Continued progress executing across the commercial portfolio • Product launches in Alzheimer's disease, rare disease, and depression each delivered sequential revenue growth; Total revenue from product launches in the third quarter continued to offset year-over-year decline in multi ...

A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021.Biogen on Wednesday reported third-quarter revenue and adjusted earnings that topped expectations while raising its full-year profit guidance, as sales of its breakthrough Alzheimer's drug, Leqembi, and other new products gain traction. Biogen now expects full-year adjusted earnings to come in between $16.10 and $16.60 per share, up from a previous forecast of $15.75 to $16.25 per share. The biotech company ...

The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen.Collaboration leverages Neomorph's leading molecular glue discovery platform and Biogen’s deep expertise in Alzheimer’s, rare, and immunological diseases. CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheime ...

Biotechnology firm Biogen Inc (NASDAQ:BIIB) is scheduled to report third-quarter results before the open on Wednesday, Oct. 30. Ahead of the event, it was announced that Biogen's Executive V.P. and Chief Financial Officer Michael McDonnel will retire in February and be replaced by Robin Kramer. At last glance, BIIB was up 2% at $185.36. BIIB has a fairly dismal post-earnings history, as it's closed lower the day after earnings in seven of the last eight quarters. Shares averaged a 5.5% move the day after ea ...